Here are the latest items added to the CTN Dissemination Library for June – July 2025 (this post will be updated as new items come in): Note: if the links below are not working, try searching in the Library by title (we’re having some technical difficulties with caching!). Medications for Opioid Use Disorder: Predictors of Early Discontinuation and Reduction of Overdose Risk in U.S. Military Veterans by Medication Type. Hayes CJ, et al. Addiction 2025;120(1):138-151. (CTN-0142) Protocol Commentary for the SUCCESS (Successful Recruitment and Retention in a Randomized Controlled Trial of Pregnant Participants with Opioid Use Disorder) Study. Snyder AM, et al. Substance Use & Addiction Journal 2025:29767342251334490. (CTN-0080-A-1) Craving, Impulsivity, and Subsequent Methamphetamine Use with Naltrexone-Bupropion Versus Placebo: Findings from a Randomized Clinical Trial. Jha MK, et al. Journal of Addiction Medicine 2025 (in press). (CTN-0068) PILOT Peer Intervention Manual. Peer Intervention to Link Overdose Survivors to Treatment (PILOT). NIDA CTN Protocol 0107. Barth K, et al. NIDA Clinical Trials Network CTN-0107 Protocol Team. (CTN-0107) Using Structural Equation Modeling to Examine Barriers and Facilitators of HIV Pre-Exposure Prophylaxis Willingness and Length of Use in Men Who Have Sex with Men Who Use Substances in Eight Southern US Cities.Ertl M, et al. AIDS Patient Care and STDs 2025;39(6):245-256. (CTN-0082) Conducting an Implementation Intervention Study with American Indian and Alaska Native Communities: Methodological Considerations. Paschen-Wolff MM, et al. Contemporary Clinical Trials 2025;107992. (CTN-0096) Posted on June 23, 2025, updated July 9, 2025

Here are the latest items added to the CTN Dissemination Library for May – June 2025 (this post will be updated as new items come in): “I Don’t Tell Anyone I Have Them”: Experiences with Opioid Stigma from the Perspective of Survivors Living with Chronic Cancer-Related Pain and Clinicians that Care for Them. Bell SG, et al. Journal of Pain 2025;32:105411. (CTN-0115) Posted on May 19, 2025.

Here are the latest items added to the CTN Dissemination Library for April – May 2025 (this post will be updated as new items come in): Randomized, Placebo-Controlled Trial of Injectable Extended-Release Naltrexone and Injectable Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2): Study Rationale and Design. Trivedi MH, et al. Contemporary Clinical Trials 2025;154:107954. (CTN-0109) Identifying Alcohol Use Disorder and Problem Use in Adult Primary Care Patients: Comparison of the Tobacco, Alcohol, Prescription Medication and Other Substance (TAPS) Tool with the Alcohol Use Disorders Identification Test Consumption Items (AUDIT-C). Adam A, et al. Substance Use & Addiction Journal 2025 (in press). (CTN-0059) Repetitive Transcranial Magnetic Stimulation for Stimulant Use Disorders (STIMULUS): Protocol for a Multi-Site, Double-Blind, Randomized Controlled Trial. Atoui Z, et al. Addiction Science & Clinical Practice 2025;20:40. (CTN-0108) Impact of Recent Stimulant Use on Treatment Outcomes Amongst Individuals Initiating Medications for Opioid Use Disorders: Secondary Analysis of a Multisite Randomized Controlled Trial. Coles C, et al. Drug and Alcohol Dependence Reports 2025;15:100330. (CTN-0027) Exploring the Impact of Reduction in Methamphetamine Use on Sexual Risk Behaviors Among Men Who Have Sex with Men and Women: Findings from the ADAPT- 2 Trial. Okafor CN, et al. International Journal of Behavioral Medicine 2025 (in press). (CTN-0068) Posted April 24, 2025. Updated May 15, 2025.

Here are the latest items added to the CTN Dissemination Library for January – February 2025 (this post will be updated as new items come in): Predictors of Participation in Prenatal Substance Use Assessment, Counseling, and Treatment Among Pregnant Individuals in Prenatal Settings Who Use Cannabis. Lapham GT, et al. Journal of Addiction Medicine 2024 (in press). (CTN-0140) Optimizing Retention Strategies for Opioid Use Disorder Pharmacotherapy: The Retention Phase of the CTN-0100 Trial (RDD). Shulman M, et al. Contemporary Clinical Trials 2025;107816 (in press). (CTN-0100) Age, Period, and Cohort Effects in Alcohol and Other Substance Use: Implications for Health and Prevention (webinar). Keyes KM. Youth Special Interest Group (SIG) webinar, January 2025. Effects of Randomization to Buprenorphine or Naltrexone for OUD on Cannabis Use Outcomes: A Secondary Analysis of the X:BOT Trial. Shulman M, et al. Drug and Alcohol Dependence 2025 (in press). (CTN-0051) Evaluating Tests for Cluster-Randomized Trials with Few Clusters Under Generalized Linear Mixed Models with Covariate Adjustment: A Simulation Study. Qui H, et al. Statistics in Medicine 2024;43(2):201-215. Posted on January 19, 2025; Updated on February 11, 2025

Here are the latest items added to the CTN Dissemination Library for December 2024 -January 2024 (this post will be updated as new items come in): Willingness to Use Oral and Long-Acting Injectable PrEP in Substance-Using Men Who Have Sex with Men (SU-MSM) in High HIV Incidence Southern U.S. Cities: A NIDA Clinical Trials Network Study. Tross S, et al. AIDS and Behavior 2024 (in press). (CTN-0082 outcomes) HIV Prevention in Syringe Service Programs Since the Start of COVID-19: Where Do We Go From Here? Hatch MA, et al. Current HIV/AIDS Reports 2025;22:13. Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. Lu T, et al. Annals of Emergency Medicine 2024 (in press). (CTN-0069) Racial and Ethnic Differences in Long-Term Outcomes Among Individuals with Opioid Use Disorder at Opioid Treatment Programs. Zhu Y, et al. Journal of Racial and Ethnic Health Disparities 2024 (in press). (CTN-0050) Data Cleaning and Harmonization of Clinical Trial Data: Medication-Assisted Treatment for Opioid Use Disorder. Balise RR, et al. PLoS ONE 2024;19(11):e0312695. (CTN-0027, CTN-0030, CTN-0051) Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial. Lapham GT, et al. JAMA Network Open 2024;7(11):e2447447. (CTN-0074) Posted on January 7, 2025.

Here are the latest items added to the CTN Dissemination Library for November-December 2024 (this post will be updated as new items come in): Factors Associated with PrEP Awareness and Use Among Men Who Have Sex with Men Who Use Drugs in the Southern United States. Paschen-Wolff M, et al. AIDS Care 2024 (in press). (CTN-0082) Efficient and Flexible Mediation Analysis with Time-Varying Mediator, Treatments, and Confounders. Díaz I, Journal of Causal Inference 2023;11(1):20220077. (CTN-0051) Pharmacy-Based Preventive Services for Opioid Use Disorder: A Survey of U.S. Pharmacists. Wu L, et al. Addiction Science & Clinical Practice 2024;19:88. (primary outcomes for CTN-0105) CTN-0138: Adaptation, Implementation, and Cluster Randomized Trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool — A Protocol Paper. Cochran GT, et al. Addiction Science & Clinical Practice 2024;19:82. (CTN-0138) Artificial Intelligence-Based Drug Repurposing with Electronic Health Record Clinical Corroboration: A Case for Ketamine as a Potential Treatment for Amphetamine-Type Stimulant Use Disorder. Gao Z, et al. Addiction 2024 (in press). (CTN-0114) Posted November 18, 2024, updated December 18, 2024

Here are the latest items added to the CTN Dissemination Library for October-November 2024 (this post will be updated as new items come in): Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention. Afshar M, et al. Journal of Addiction Medicine 2024;18(5):511-519. (CTN-0051) Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. Ross RK, et al. JAMA Network Open 2024;7(10):e2436612. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. Nunes EV, et al. American Journal of Psychiatry 2021;178(7):660-671. (CTN-0051) Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. Fishman M, et al. American Journal on Addiction 2021;30(5):433-444. (CTN-0051) Nonparametric Causal Mediation Analysis for Stochastic Interventional (In)direct Effects. Hejazi NS, et al. Biostatistics 2023;24(3):686-707. (CTN-0051) Polysubstance Use Before and During Treatment with Medication for Opioid Use Disorder: Prevalence and Association with Treatment Outcomes. Bunting AM, et al. Journal of Substance Abuse Treatment 2022;143:108830. (CTN-0051) Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder. Gopaldas M, et al. Psychiatric Services 2023;74(12):1227-1233. (CTN-0051) Clinical and Psychosocial Outcomes by Sex Among Individuals Prescribed Buprenorphine-Naloxone (BUP-NX) or Extended-Release Naltrexone (XR-NTX) for Opioid Use Disorder. Paschen-Wolff M, et al. American Journal on Addiction 2023;32(6):584-592. (CTN-0051) Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder. Shulman M, et…

Here are the latest items added to the CTN Dissemination Library for September– October 2024 (this post will be updated as new items come in): Falling Through the Cracks: The Struggle of Adolescents with Opioid Use Disorder in the Face of Limited Treatment Options. Kaliamurty S. Youth Special Interest Group (SIG) webinar, September 2024. Changes in Prenatal Cannabis Use Among Pregnant Individuals From 2012 to 2022. Young-Wolff KC, et al. Obstetrics & Gynecology 2024;144(4):e101-e104. (CTN-0104) Effectiveness of a Vaping Cessation Text Message Program Among a Diverse and High-Risk Sample of Adolescent E-Cigarette Users (webinar recording). Graham AL. Youth Special Interest Group (SIG) webinar, September 2024. Peer Intervention to Link Overdose Survivors to Treatment (PILOT): Protocol for a Multisite, Randomized Controlled Trial Conducted Within the National Institute on Drug Abuse Clinical Trials Network. Papa C, et al. JMIR Research Protocols 2024;13:e60277. (CTN-0107)